Cafepharma Today

June 5 2025 - GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
GLP-1 drugs may be linked to elevated risk of serious eye disease, study finds
Bispecific cancer drugs, data caveats and funding alarms: 3 takeaways from ASCO
FDA’s Elsa AI is here, and the industry has questions
Merck gains U.S. patent office support in Keytruda dispute
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Article retractions muddy MDMA waters after FDA denial
Pharmaphorum
Monday, August 12, 2024 - 11:23am
tags:
MDMA, Lykos Therapeutics, PTSD, FDA, psychedelics
Biotech giant Amgen announces new office in tech-savvy Hyderabad
Investment Monitor
Sunday, August 11, 2024 - 10:39pm
tags:
Amgen, India, Hyderabad
Lykos will ask FDA to reconsider its decision following rejection of MDMA therapy for post-traumatic stress disorder
Fierce Biotech
Sunday, August 11, 2024 - 1:09pm
tags:
Lykos Therapeutics, FDA, MDMA, PTSD, midomafetamine
FDA approves nasal spray alternative to EpiPen for allergic reactions
Reuters
Sunday, August 11, 2024 - 1:07pm
tags:
FDA, ARS Pharmaceuticals, allergic reactions, anaphylaxis, EpiPen, Neffy
Merck bets $700M on an antibody drug’s potential in immune diseases
BioPharma Dive
Friday, August 9, 2024 - 11:57am
tags:
Merck, autoimmune disease, Curon Biopharmaceutical, China, bispecific antibodies
With pharma in ‘catbird seat,’ biotechs get less upfront in drug partnerships
BioPharma Dive
Friday, August 9, 2024 - 11:55am
tags:
biotech, licensing
Pulse Biosciences launches first-in-human pulsed field ablation trial
Clinical Trials Arena
Friday, August 9, 2024 - 11:32am
tags:
Pulse Biosciences, atrial fibrillation, pulsed field ablation, clinical trials, Medtech
Legend Biotech CEO takes ‘close look at business’ amid geopolitical risk, M&A rumor
Fierce Pharma
Friday, August 9, 2024 - 11:31am
tags:
Legend Biotech, Pharma CEOs, Ying Huang, CAR-T, Carvykti, M&A
MDMA therapy is facing an imminent FDA decision. Here’s what you need to know
Stat
Friday, August 9, 2024 - 11:29am
tags:
FDA, MDMA, psychedelics, Lykos Therapeutics, PTSD
CMS finalizes notice on Medicare coverage for breakthrough devices
Medtech Dive
Friday, August 9, 2024 - 11:27am
tags:
CMS, Medicare, Medtech, breakthrough devices
Cepheid to cut more than 600 employees in California
Medtech Dive
Friday, August 9, 2024 - 11:26am
tags:
Cepheid, layoffs, California, diagnostics, Medtech
Sandoz lifts guidance after Humira biosimilar drives another quarter of sales growth
Fierce Pharma
Friday, August 9, 2024 - 11:25am
tags:
Sandoz, earnings, biosimilars, Humira, AbbVie, Novartis
IRA Reality Check: Four Strategies for Adapting Hub and Copay Programs
Drug Channels
Friday, August 9, 2024 - 11:25am
tags:
Inflation Reduction Act, drug pricing, copays
On doorstep of FDA decision, Gilead pays J&J $320M to exit licensing deal for seladelpar
Fierce Biotech
Friday, August 9, 2024 - 11:23am
tags:
Gilead Sciences, seladelpar, liver disease, JNJ
Pharma execs react to final drug price negotiations with Medicare
Pharma Voice
Friday, August 9, 2024 - 11:21am
tags:
Medicare, drug pricing, Inflation Reduction Act, Bristol Myers Squibb, Eli Lilly, JNJ, Bayer, Merck, AstraZeneca, Novartis, Amgen, AbbVie, Novo Nordisk
Lilly's tau drug for Alzheimer's flunks phase 2 test
Pharmaphorum
Friday, August 9, 2024 - 11:18am
tags:
Eli Lilly, Alzheimer's disease, clinical trials, LY3372689
Aldeyra shows FDA-rejected reproxalap improves eye discomfort in new phase 3 study
Fierce Biotech
Thursday, August 8, 2024 - 10:25pm
tags:
Aldeyra Therapeutics, dry eye disease, reproxalap, FDA
Gilead quarterly profit beats Street estimates, revenue up 5%
Yahoo/Reuters
Thursday, August 8, 2024 - 10:24pm
tags:
Gilead Sciences, earnings
FDA approves Citius' therapy for rare blood cancer
Reuters
Thursday, August 8, 2024 - 10:19pm
tags:
Citius Pharmaceuticals, FDA, Lymphir, cutaneous T-cell lymphoma
Will Magenta Medical’s Elevate Disrupt the MCS Market?
Medical Devices and Diagnostics Industry
Thursday, August 8, 2024 - 10:17pm
tags:
Medtech, Magenta Medical, MCS, Elevate, JNJ, Impella

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline
Inside a Scientific Paper Mill
In the Pipeline
Autoimmune Disease, Transformed?
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.